用于输送脂性药物的双体和双粒子:一项初步研究
Maddalena Sguizzato1, Francesca Ferrara1, Nada Baraldo1
1Department of Chemical, Pharmaceutical and Agricultural Sciences (DoCPAS), University of Ferrara, I-44121 Ferrara, Italy.
Antioxidants (Basel, Switzerland)
|December 23, 2023
概括
胆酸纳米颗粒,称为双体和双颗粒,增强脂性药物溶解性,减少炎症. 双粒子在肠道细胞中改善了药物输送和疗效.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术 纳米技术
背景情况:
- 脂性药物往往因水溶性差而受到影响,从而限制了它们的治疗效果.
- 胆汁酸,天然表面活性剂,为制备难溶性化合物提供了潜力.
- 双体和双粒子是从胆汁酸中衍生出来的新型纳米载体.
研究的目的:
- 研究基于胆汁酸的囊泡 (双体) 和纳米颗粒 (双颗粒) 提高脂性药物的溶解性和输送的潜力.
- 评估这些纳米载体的封装效率,稳定性和体外药物释放特性.
- 评估在肠道细胞中的布塞尼德载荷比洛索姆的抗炎作用.
主要方法:
- 使用ursodeoxycholic酸,胆酸盐和陶酸盐制备双体和双颗粒.
- 布德索尼德的封装作为一种模范性脂友药物.
- 在体外药物释放研究中,使用尼龙膜透析或Wistar大鼠小肠段在模拟的胃和肠液中进行透析.
- 免疫光测试以评估抗炎作用.
主要成果:
- 双体和双粒子表现出良好的封装效率和尺寸稳定性.
- 与ursodeoxycholic 酸相比,二氧化颗粒中的封装效率增加了与胆酸和陶酸相比.
- 与参考溶液相比,双粒体和双粒体的药物释放速度较慢,双粒体显示出布索尼德通过水溶液的增强.
- 荷载着布德索尼德的乌尔索多胆酸双体细胞有效地降低了肠道细胞中的炎症反应.
结论:
- 基于胆汁酸的纳米载体 (双体和双粒子) 对提高脂性药物的可溶性和输送具有前景.
- 双颗粒提供了更好的封装效率和药物释放特性.
- Ursodeoxycholic 酸双体体通过减少肠道细胞的炎症和氧化损伤,显示出潜在的治疗益处.
相关概念视频
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:17Bioavailability: Overview
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
01:16Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...